Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

The Use of Temozolomide for the Treatment of Malignant Tumors: Clinical Evidence and Molecular Mechanisms of Action

Author(s): Roberto Bei, Laura Marzocchella and Mario Turriziani

Volume 5, Issue 3, 2010

Page: [172 - 187] Pages: 16

DOI: 10.2174/157489210791760526

Price: $65

Abstract

Temozolomide (TMZ) is a monofunctional methylating agent which is spontaneously activated in aqueous solution into the dacarbazine metabolite 5-(3-methyl-1-triazeno)imidazole-4-carboxamide. This drug has been approved for the treatment of metastatic melanoma and glioblastoma multiforme, the latter in combination with radiotherapy. Furthermore, clinical trials have been performed to assess the activity of TMZ, alone or in combination, on brain metastatic solid tumors and leukaemias. This review will report clinical evidence on the use of TMZ for the treatment of different types of cancer; it also considers current knowledge on TMZs molecular mechanisms of action of and discusses relevant patents relating to the same drug.

Keywords: Anti-cancer drug, alkylating drug, DNA damage, temozolomide, triazenes

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy